Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies

Anja Garritsen, Anja Scholzen, Daan W.A. van den Nieuwenhof, Anke P.F. Smits, E. Suzan Datema, Luc S. van Galen, Milou L.C.E. Kouwijzer
doi: https://doi.org/10.1101/2020.10.07.20187641

Article Information

doi 
https://doi.org/10.1101/2020.10.07.20187641
History 
  • October 28, 2020.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Anja Garritsen1,#+,
  2. Anja Scholzen1,#,
  3. Daan W.A. van den Nieuwenhof1,
  4. Anke P.F. Smits1,
  5. E. Suzan Datema1,
  6. Luc S. van Galen1 and
  7. Milou L.C.E. Kouwijzer1
  1. 1Innatoss Laboratories B.V., Oss, The Netherlands
  1. ↵+Corresponding author: anja.garritsen{at}innatoss.com, Kloosterstraat 9 RE21, Room 3124, 5349 AB Oss, The Netherlands

  1. ↵# Authors contributed equally

Back to top
Posted October 28, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies
Anja Garritsen, Anja Scholzen, Daan W.A. van den Nieuwenhof, Anke P.F. Smits, E. Suzan Datema, Luc S. van Galen, Milou L.C.E. Kouwijzer
medRxiv 2020.10.07.20187641; doi: https://doi.org/10.1101/2020.10.07.20187641
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area